Viral Vector Manufacturing Patents: Who Leads, Where Gaps Are 2026
- 42.9% concentration. The top 5 of 64 ranked assignees hold 109 of 254 records in scope — filing is concentrated at the head of the field.
- Filing has plateaued. Activity peaked at 46 records in 2022 and has since flattened, with the leading assignees logging zero filings in the latest year.
- Bioreactor and QC claims are thin. C12M (bioreactors) and C12Q (enzyme/DNA testing) each sit under 4% of records, well behind the core genetic-engineering and formulation classes.
What this patent set covers
This landscape covers 254 published records filed against a search built around AAV and lentiviral vector manufacturing: transfection efficiency, full-to-empty capsid ratio, titer, downstream purification and suspension culture, filtered against IPC classes for microorganism engineering, gene technology and bioreactor apparatus. The scope spans 2015 through mid-2026, with the 2026 count necessarily partial because publication typically lags filing by around 18 months.
The record set groups into a small number of well-defended process claims — cell line and vector construct engineering, transfection reagent formulation, culture supplement chemistry — sitting alongside a much thinner layer of downstream purification and analytical/QC filings. That asymmetry is itself a signal: the upstream production chemistry is heavily claimed, while process analytics and scale-up hardware are comparatively open.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology mix
Two views of the same 254 records: how filing activity has moved year over year, and which IPC subclasses carry the claim density.
Filing trend, 2017–2026
Filings rose from 5 in 2017 to a peak of 46 in 2022, then flattened toward zero by 2026 — a partial-year figure consistent with publication lag rather than a genuine drop-off, though the leading assignees show no new filings in the latest year tracked.
IPC subclass composition
C12N (microorganisms and genetic engineering) appears in 98.8% of the 254 records, effectively defining the field; A61K (medicinal preparations, 29.9%) and C07K (peptides and proteins, 22.8%) follow. Bioreactor apparatus (C12M, 3.5%) and enzymatic/DNA testing (C12Q, 2.8%) are the thinnest classes, and a record can carry more than one class so these shares sum above 100%.
Shares are the percentage of the 254 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Viral Vector Manufacturing (AAV and Lentivirus) with Eureka
This page is one run against one query. Ask Eureka your own question about viral vector manufacturing (aav and lentivirus) and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in the corpus
US20220348964A1 — Serum-free suspension system for lentiviral production
A lentiviral vector production system combining a culture supplement to control cell growth, a transfection reagent built on DHDMS, DOPE and cholesterol, and a production enhancer of sodium propionate, sodium butyrate and caffeine, run entirely serum-free. The filing also claims methods for culturing eukaryotic cells in serum-free medium and transfecting them using this reagent chemistry.Filed by Life Technologies Corporation, published 2022-11-03.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1999041397A1 | Anti-viral vectors | 348 |
| 2 | US7629153B2 | Methods and compositions relating to improved lentiviral vector production systems | 105 |
| 3 | US8900858B2 | Methods and compositions relating to improved lentiviral vector production systems | 90 |
| 4 | WO2015092440A1 | Viral vector production system | 82 |
| 5 | WO2003039459A2 | Viral vector production methods and compositions | 69 |
| 6 | US9260725B2 | Methods and compositions relating to improved lentiviral vector production systems | 54 |
| 7 | US20160333373A1 | Viral Vector Production System | 41 |
| 8 | US20150203870A1 | Methods and compositions relating to improved lentiviral vector production systems | 33 |
| 9 | WO2013076309A1 | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications | 31 |
| 10 | US20180327722A1 | Methods for Adeno-Associated Viral Vector Production | 30 |
Citation counts reflect a searched corpus and skew toward older filings; treat them as a measure of influence on later claim drafting, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three read-throughs from the concentration, trend and classification figures above.
The field has a defined head, then a long tail
Five assignees out of 64 ranked account for 109 of the 254 records in scope. That level of concentration means core transfection and vector-production claims are likely already occupied by a small number of filers, and new entrants should expect to design around rather than file directly into that space.
Growth has flattened, not accelerated
The filing trend rises to a midpoint peak of 46 records in 2022 and declines toward the present, with several of the largest historical filers showing zero activity in the latest year tracked. Read the final year or two as understated due to publication lag rather than as a genuine collapse in R&D activity.
Hardware and QC claims are thinly filed
Bioreactor and enzyme apparatus claims (C12M) sit at 3.5% of the 254 records, and enzymatic/DNA measurement claims (C12Q) at 2.8%. Both are far behind the 98.8% C12N core, suggesting that scale-up hardware and analytical QC methods carry less accumulated prior art than the underlying vector and reagent chemistry.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to viral vector manufacturing (aav and lentivirus), with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Fondazione Telethon | Bioverativ Therapeutics Inc | 13 |
| Fondazione Telethon | Ospedale San Raffaele Srl | 13 |
| Bioverativ Therapeutics Inc | Ospedale San Raffaele Srl | 13 |
| Asklepios BioPharmaceutical Inc | Sepromax Ltd | 7 |
| Asklepios BioPharmaceutical Inc | WHYTESIDE GRAHAM | 4 |
| Asklepios BioPharmaceutical Inc | ROBERTS MICHAEL L | 4 |
| Oxford Biomedica (UK) Ltd | MITROPHANOUS KYRIACOS | 1 |
| Oxford Biomedica (UK) Ltd | KINGSMAN ALAN JOHN | 1 |
Nine co-assignee pairs appear in the dataset, with the strongest pairings each linked across 13 shared records — evidence of sustained joint-development relationships around specific vector platforms rather than one-off collaborations.
Who is filing, and where the openings sit
The ranked assignee list covers 64 companies and research institutions across the full 254-record set — not a top-50 or top-100 cut, but the whole ranking the dataset returns.
One assignee holds a clear lead
The top-ranked assignee holds 40 of the 254 records, well ahead of the fifth-place assignee at 13 and tenth place at 10 — a steep drop-off that marks a genuine leader rather than a crowded plateau at the top.
Historical leaders have gone quiet
Several of the most active historical filers, including the top-ranked assignee, show zero filings in the latest tracked year, with one recording a -100% year-on-year change. That pattern is consistent with either a maturing platform or a shift in filing strategy toward trade secret protection for process know-how.
Filing is anchored in the US and Europe
The United States (59) and the European Patent Office (50) are the largest receiving offices, followed by WIPO/PCT filings (44), with Australia, Canada and Hong Kong each carrying smaller but non-trivial counts. A freedom-to-operate check should prioritise US and EPO prosecution history before other jurisdictions.
| Assignee | Recent year | YoY |
|---|---|---|
| Oxford Biomedica (UK) Ltd | 0 | — |
| Asimov Inc | 0 | — |
| Genethon | 0 | — |
| MeiraGTx UK II Ltd | 0 | — |
| University of Massachusetts | 0 | -100% |
| Fondazione Telethon | 0 | — |
| Bioverativ Therapeutics Inc | 0 | — |
| Ospedale San Raffaele Srl | 0 | — |
Where to take this analysis
The figures above establish the shape of the field; the next step is usually claim-level comparison against a specific product or process.
Map a specific process against the leaders' claims
Run the transfection reagent, culture supplement or purification method you are developing against the claim scope of the top-ranked assignees identified here before committing to a manufacturing route.
Explore in Patsnap Eureka →Track the thin classes for early filing opportunities
C12M and C12Q remain lightly claimed relative to the C12N core; a monitoring watch on new filings in those subclasses can surface openings before they close.
Set up a watch in Patsnap Eureka →Common questions on viral vector manufacturing patents
One assignee leads clearly with 40 of the 254 records in this dataset, well ahead of the fifth-ranked assignee at 13 and tenth place at 10. The top 5 assignees together account for 42.9% of all 254 records, and the top 10 reach 64.6%. That said, 64 companies and institutions appear in the full ranking, so there is a long tail of single- or low-digit-filing entrants behind the leaders.
Filing activity rose from 5 records in 2017 to a peak of 46 in 2022, then declined toward the present, with 2026 figures necessarily partial since this dataset's cut-off is mid-year and publication typically lags filing by about 18 months. Several of the most active historical assignees show zero filings in the latest tracked year. The honest read is a plateau rather than continued acceleration, though the final one to two years should not be read as a hard decline until later publications catch up.
The IPC composition shows C12N (microorganisms and genetic engineering) present in 98.8% of the 254 records, meaning vector and reagent chemistry claims are densely occupied. Bioreactor and apparatus claims (C12M, 3.5%) and enzymatic/DNA measurement methods (C12Q, 2.8%) are comparatively thin, pointing to scale-up hardware and in-process analytics as the more open branches for new claims.
This filing, assigned to Life Technologies Corporation and published 2022-11-03, claims a serum-free lentiviral production system combining a specific culture supplement, a transfection reagent built on DHDMS, DOPE and cholesterol, and a production enhancer of sodium propionate, sodium butyrate and caffeine. It also claims methods of culturing cells and transfecting them using that reagent chemistry. Anyone building a serum-free lentiviral process with a similar reagent stack should review this claim set closely rather than assume the components are individually free to use in combination.
The United States (59 records) and the European Patent Office (50 records) are the two largest receiving offices in this dataset, followed by WIPO/PCT filings (44), with Australia (21), Canada (17) and Hong Kong (12) trailing behind. A freedom-to-operate review focused on US and EPO prosecution history will cover the large majority of enforceable claim scope in this field, with PCT filings worth checking for applications still entering national phase.
Research Viral Vector Manufacturing (AAV and Lentivirus) in depth with Eureka
Go past this page: query the whole viral vector manufacturing (aav and lentivirus) corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.